ABUS · XBRL financial data

Arbutus Biopharma financial statements, every fiscal year

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ABUS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	7	11	39	18	6	14
Research and development	47	66	84	74	54	25
General and administrative	15	17	18	22	22	16
Total operating expenses	65	85	104	96	82	52
Operating income (loss)	(58)	(74)	(65)	(78)	(76)	(38)
Interest income	1	0	2	6	7	4
Interest expense	4	3	2	0	0	0
Income tax expense (benefit)	0	0	4	0	0	0
Net income (loss)	(64)	(76)	(69)	(73)	(70)	(34)
Earnings per share, basic USD per share	(1.00)	(0.83)	(0.46)	(0.44)	(0.38)	(0.17)
Earnings per share, diluted USD per share	(1.00)	(0.83)	(0.46)	(0.44)	(0.38)	(0.17)
Weighted average shares, basic millions of shares	76	106	151	166	186	192
Weighted average shares, diluted millions of shares	76	106	151	166	186	192

Fiscal years (ABUS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	52	109	31	26	36	18
Short-term investments	71	46	116	100	86	73
Marketable securities	71	46	116	100	86	73
Marketable securities, non-current	0	—	—	6	—	—
Accounts receivable	1	1	1	2	2	1
Prepaid and other current assets	3	4	3	4	2	2
Total current assets	128	161	151	132	127	94
Property and equipment, net	7	6	5	5	3	0
Right-of-use asset	2	2	2	1	1	0
Total assets	137	204	195	144	132	95
Total current liabilities	10	11	33	22	16	6
Lease liability, non-current	3	2	2	1	1	0
Total liabilities	35	35	59	38	34	18
Accumulated deficit	(1,046)	(1,134)	(1,204)	(1,277)	(1,347)	(1,380)
Total stockholders' equity	102	169	137	106	97	77
Total liabilities and equity	137	204	195	144	132	95
Common shares outstanding (cover page) millions of shares	96	149	163	179	191	195

Fiscal years (ABUS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(64)	(76)	(69)	(73)	(70)	(34)
Stock-based compensation	6	6	7	9	9	7
Net cash from operating activities	(51)	(68)	(35)	(86)	(65)	(40)
Purchases of property and equipment	0	1	1	1	0	0
Net cash from investing activities	(15)	(13)	(75)	51	23	16
Proceeds from issuing common stock	86	135	—	—	—	—
Net cash from financing activities	87	137	32	31	52	6
Net change in cash	20	57	(79)	(4)	10	(18)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arbutus Biopharma	19	1	(6)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88	0.5	(10)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16	not reported	(9.4)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122	38	10*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Theravance Biopharma	220	21	(7)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.